VYNE Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-28.45	-23.21	-73.33	-255.57	-95.18	-74.16	-29.08	-14.07	-4.61
Depreciation & Amortization	0	0.07	0.11	0.34	0.35	0.32	0.01	0	0
Share-Based Compensation	3.31	4.3	8.08	18.1	4.9	5.32	1.45	0.57	0.07
Other Operating Activities	-0.19	-10.36	8.77	100.05	16.54	-0.14	-0.61	11.23	0.36
Operating Cash Flow	-25.34	-29.2	-56.37	-137.08	-73.39	-68.66	-28.22	-2.27	-4.18
Capital Expenditures	0	0	0	-0.11	-1.02	-0.56	-0.03	-0.03	0
Acquisitions	5	15.67	0	38.64	0	0	0	0	0
Change in Investments	-62.35	0	1.03	50.58	42.89	-11.2	-15.06	-37.49	0
Investing Cash Flow	-57.35	15.67	1.03	89.11	41.87	-11.76	-15.09	-37.52	0
Share Issuance / Repurchase	82.82	1.47	76.5	61.95	14.08	92.37	0.03	0	0.1
Debt Issued / Paid	0	0	-36.43	0	33.9	0	0	0	0
Other Financing Activities	-0.43	0.18	-0.29	-0.14	-0.03	-	49.46	-	47.62
Financing Cash Flow	82.39	1.65	39.78	61.81	47.95	92.37	49.49	0	47.72
Exchange Rate Effect	0	0	0	0	0.04	-0.04	0	0	0
Net Cash Flow	-0.3	-11.88	-15.56	13.83	16.43	11.96	6.18	-39.78	43.54
Free Cash Flow	-25.34	-29.2	-56.37	-137.2	-74.41	-69.22	-28.25	-2.3	-4.18
Free Cash Flow Margin	-5976.65%	-6121.59%	-6054.46%	-653.53%	-16797.29%	-1925.48%	-616.52%	-340.65%	-
Free Cash Flow Per Share	-2.47	-9.16	-19.72	-76.18	-157.86	-192.70	-398.18	-33.15	-63.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).